BB708B Metabolite 1

**BB708B Metabolite 1** is a BalinBac Therapeutics COVID-19 pipeline asset described as a metabolite of BB708B and as part of a repurposed-generic-drug combination strategy. BalinBac characterizes the BB-700-series approach as using multiple proposed anti-SARS-CoV-2 mechanisms, including viral entry or attachment inhibition, spike or protease modulation, protease inhibition, RNA-dependent RNA polymerase inhibition, metabolic-response inhibition, and enzyme activation. The specific chemical identity and active-component composition of BB708B Metabolite 1 have not been publicly disclosed in the available pipeline information. ([balinbac.com](https://www.balinbac.com/pipeline))